Clinical trial
Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat…
NCT00481871 · Acrotech Biopharma Inc., Industry · Completed
Key facts
| NCT number | NCT00481871 |
|---|---|
| Title | Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies |
| Official title | A Phase 1/2a Open-label Study of Pralatrexate and Gemcitabine With Vitamin B12 and Folic Acid Supplementation in Patients With Relapsed or Refractory Lymphoproliferative Malignancies |
| Lead sponsor | Acrotech Biopharma Inc., Industry |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Relapsed or Refractory Lymphoproliferative Malignancies, Hodgkin's Lymphoma, Peripheral T-cell Lymphoma, B-cell Lymphoma, Waldenstrom's Macroglobulinemia |
| Intervention type | Dietary Supplement, Drug |
| Interventions | Pralatrexate Injection, Gemcitabine Hydrochloride, Vitamin B12, Folic Acid |
| Enrollment | 119 |
| Start date | May 1, 2007 |
| Primary completion | May 1, 2011 |
| Completion | Aug 1, 2011 |
| First posted | Jun 4, 2007 |
| Last update posted | Jan 7, 2020 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: